Antibiotic Use Before CAR-T Treatment Is Associated with Inferior Outcomes in DLBCL Lymphoma Patients.

Anja Bullegas, Inna Shaforostova, Katja Seipel, Marie-Noëlle Kronig, Henning Nilius, Ulrike Bacher, Thomas Pabst

Abstract read

In one paragraph

Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Microbiota-derived metabolic priming of CAR-T cell fitness: a translational framework for next-generation cell therapy.Frontiers in immunology · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anja BullegasDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.

Inna ShaforostovaDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-0592-091X

Katja SeipelDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0003-3128-1573

Marie-Noëlle KronigDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.

Henning NiliusCenter for Laboratory Medicine, Department of Clinical Chemistry, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-1323-3116

Ulrike BacherCentral Hematology Laboratory, Department of Hematology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0001-8771-947X

Thomas PabstDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-6055-5257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibiotic treatmentCAR-T-cell therapyDLBCLmicrobiome

Identifiers

PMID41751197

DOI10.3390/biomedicines14020298

PMCPMC12937898

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.